Brief: Iteos Therapeutics Announces New Phase 1/2A Data Indicating Antitumor Activity Of Inupadenant, Its Adenosine A2a Receptor Antagonist, At Asco 2021
04/06/2021 14:14
June 4 (Reuters) - Iteos Therapeutics Inc ITOS.O :
* ITEOS THERAPEUTICS ANNOUNCES NEW PHASE 1/2A DATA
INDICATING
ANTITUMOR ACTIVITY OF INUPADENANT, ITS ADENOSINE A2A RECEPTOR
ANTAGONIST, AT ASCO 2021
* ITEOS THERAPEUTICS INC - SINGLE-AGENT ADMINISTRATION OF
INUPADENANT WAS WELL TOLERATED, CONSISTENT WITH PREVIOUSLY
REPORTED SAFETY DATA
Source text for Eikon: ID:nGNE5NG9dC
Further company coverage: ITOS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on iTeos Therapeutics
See all newsIteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Iteos Therapeutics Enters Into Agreement To Be Acquired By Concentra Biosciences For $10.047 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Sonic Automotive